Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035995 | 0.89 | IDO1 (0.49) | POLBNPC1LMNARAB9AHTT | |
| SCHEMBL14249218 | 0.84 | LMNA (0.47) | POLBNPC1LMNARAB9AGABRA2 | |
| SCHEMBL14248904 | 0.83 | POLB (0.46) | POLBNPC1LMNARAB9AGABRA2 | |
| SCHEMBL14248701 | 0.82 | POLB (0.45) | POLBNPC1LMNARAB9AGABRA2 | |
| SCHEMBL22200913 | 0.80 | TSHR (0.47) | NPC1LMNARAB9AGABRA2GABRB2 | |
| SCHEMBL14248834 | 0.79 | TDP1 (0.48) | HPGDMEN1KMT2AALDH1A1MAPK1 | |
| SCHEMBL14249518 | 0.76 | GABRA2 (0.49) | POLBNPC1LMNARAB9AGABRA2 | |
| SCHEMBL14248954 | 0.76 | GRM5 (0.34) | POLBNPC1RAB9AHPGDMEN1 | |
| SCHEMBL31082928 | 0.76 | GAA (0.50) | LMNAHTTHPGDKMT2AMAPT | |
| SCHEMBL14317897 | 0.76 | MAPK1 (0.48) | POLBNPC1LMNARAB9AGABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703776-B2 | Agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2012174164-A2 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174164-A2 | AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059856-A1 | AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR27 | POLB 4636/4885NPC1 872/4885LMNA 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.